Results 211 to 220 of about 785,669 (310)

Microfluidics Lab‐on‐a‐Chip Approaches to Decipher Atherosclerosis Pathogenesis

open access: yesSmall, EarlyView.
Figure created with BioRender.com. This review highlights how microfluidic lab‐on‐a‐chip models recreate key features of atherosclerosis in controlled, human‐relevant environments. It summarizes advances in modeling endothelial dysfunction, immune cell recruitment, foam cell formation, vascular remodeling, stenosis, and plaque rupture.
Fahima Akther, Hang Thu Ta
wiley   +1 more source

Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins. [PDF]

open access: yesMAbs, 2017
Spidel JL   +8 more
europepmc   +1 more source

HER2‐Targeted AIE Nanotheranostics Overcome SHR‐A1811 Resistance via Immunogenic Pyroptosis and Tumor‐Associated Macrophage Reprogramming in Breast Cancer

open access: yesSmall, EarlyView.
HER2‐targeted AIE780‐A1811 nanoparticles self‐assemble via amide coupling of a mitochondria‐directed photosensitizer with the ADC SHR‐A1811. Upon 660 nm irradiation, they generate ROS, photothermal effects, and controlled drug release, inducing immunogenic pyroptosis and M2‐to‐M1 macrophage reprogramming. This dual action remodels the immunosuppressive
Xiaohong Liu   +12 more
wiley   +1 more source

Biomaterial Platforms for Spatiotemporal Control of mRNA Delivery in Tissue Engineering and Regenerative Medicine: Design Rules, Therapeutic Applications, and Translational Roadmap

open access: yesSmall, EarlyView.
Biomaterial platforms can control where and when mRNA‐encoded proteins are expressed to support tissue repair. This Review proposes a cargo–target–timing framework linking therapeutic function, target tissues and cells, and expression profiles with carrier and scaffold design.
Huachun Pan   +14 more
wiley   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

open access: yesSmart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou   +4 more
wiley   +1 more source

The Utility of Intranasal Corticosteroids in Association With Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: A Real‐Life Multicenter Study by a Tuscany Group

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type‐2 diseases. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has revolutionized the treatment of severe CRSwNP.
Pietro Orlando   +17 more
wiley   +1 more source

Xenotransplantation at a Crossroads: Breakthroughs, Challenges, and the Path Forward

open access: yes
Organ Medicine, EarlyView.
Xiaoyu Gan   +3 more
wiley   +1 more source

Effectiveness and Safety of Vunakizumab Over 12 Weeks in Chinese Patients With Plaque Psoriasis: A Prospective, Real‐World Cohort Study

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Vunakizumab is a humanized anti‐IL‐17A monoclonal antibody approved in China for moderate‐to‐severe plaque psoriasis. Real‐world data on its effectiveness and predictors of response remain scarce. This prospective, single‐center, observational study enrolled 34 adults receiving vunakizumab (240 mg subcutaneously at weeks 0, 2, and 4, then ...
Tong Wu   +4 more
wiley   +1 more source

Nimotuzumab Combined With Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma: A Systematic Review and Meta‐Analysis

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
This meta‐analysis of 18 studies (3962 patients) demonstrates that nimotuzumab combined with chemoradiotherapy significantly improves overall survival and progression‐free survival in locally advanced head and neck squamous cell carcinoma, without increasing severe toxicity.
Chengzheng Bao   +6 more
wiley   +1 more source

PRL3-zumab, a first-in-class humanized antibody for cancer therapy. [PDF]

open access: yesJCI Insight, 2016
Thura M   +23 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy